{"id":"NCT02840461","sponsor":"Actavis Inc.","briefTitle":"Clinical Endpoint Study of Ivermectin 1% Cream","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2016-11","completion":"2016-12","firstPosted":"2016-07-21","resultsPosted":"2020-06-02","lastUpdate":"2020-06-02"},"enrollment":630,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"Ivermectin Cream, 1%","otherNames":[]},{"type":"DRUG","name":"Placebo/Vehicle cream","otherNames":[]}],"arms":[{"label":"Ivermectin Cream, 1%","type":"EXPERIMENTAL"},{"label":"SoolantraTM (ivermectin) Cream, 1%","type":"ACTIVE_COMPARATOR"},{"label":"Placebo/Vehicle cream","type":"PLACEBO_COMPARATOR"}],"summary":"A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.","primaryOutcome":{"measure":"Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.","timeFrame":"Baseline and 12 Weeks","effectByArm":[{"arm":"Ivermectin Cream, 1%","deltaMin":-64.87,"sd":2.03},{"arm":"SoolantraTM (Ivermectin) Cream, 1%","deltaMin":-64.87,"sd":2.03},{"arm":"Vehicle Cream","deltaMin":-55.04,"sd":2.92}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":"0.0027"},{"comp":"OG001 vs OG002","p":"0.0028"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":259},"commonTop":["Headache","Myalgia","Dermatitis contact","Application site pain","Nasopharyngitis"]}}